Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin

Transplantation

Volumn 96, Issue 3, 2013, Pages 306-315

  Donckier, Vincent ^a   Craciun, Ligia ^b   Miqueu, Patrick ^b   Troisi, Roberto Ivan ^c   Lucidi, Valerio ^a   Rogiers, Xavier ^c   Boon, Nathalie ^a   Degré, Delphine ^a   Buggenhout, Alexis ^a   Moreno, Christophe ^a   Gustot, Thierry ^a   Sainz Barriga, Maurizio ^c   Bourgeois, Nadine ^a   Colle, Isabelle ^c   Van Vlierberghe, Hans ^c   Amrani, Mohammed ^b   Remmelink, Myriam ^a   Lemmers, Arnaud ^d   Roelen, Dave L ^d   Claas, Frans H ^e,f   Reinke, Petra ^e,f   Sawitzki, Birgit ^e,f   Volk, Hans Dieter ^b   Le Moine, Alain ^c   De Hemptinne, Bernard ^b   Goldman, Michel ^b   more..

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

Liver; Memory; T cells; Tolerance; Transplantation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; LYMPHOCYTE ANTIGEN; MESSENGER RNA; PROTEIN TCAIM; RAPAMYCIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; GAMMA INTERFERON GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTERLEUKIN 17 GENE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T CELL DEPLETION; TACHYCARDIA; WOUND DEHISCENCE;

ADULT; ANTILYMPHOCYTE SERUM; CADAVER; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-7; ISOANTIBODIES; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; SIROLIMUS;

EID: 84881610502     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182985414     Document Type: Article

References (68)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
2. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
3. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811.
4. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243.
5. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 4: 926.
6. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts the progression of disease recurrence. J Hepatol 2006; 44: 702.
7. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009; 50: 1247.
8. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplantation. JAMA 2012; 307: 283.
9. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
10. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
11. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
12. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662.
13. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520.
14. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 6: 722.
15. Beńtez CE, Puig-Pey I, Ló pez M, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010; 10: 2296.
16. Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180: 5794.
17. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338.
18. Singh K, Kozyr N, Stempora L, et al. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 2012; 12: 1441.
19. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
20. Nador RG, Hongo D, Ya Z, et al. The changed balance of regulatory and naBve T cells promotes tolerance after TLI and anti-T cell antibody conditioning. Am J Transplant 2010; 10: 262.
21. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844.
22. Ma A, Qi S, Song L, et al. Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in cynomolgus monkeys. Int Immunopharmacol 2011; 11: 618.
23. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848.
24. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187: 2072.
25. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
26. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845.
27. Bohne F, Martinez-Llordella M, Lozano JJ. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122: 368.
28. Sànchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl 2011; 17: S69.
29. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480.
30. Bühler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
31. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
32. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386.
33. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362.
34. Donckier V, Troisi R, Toungouz M, et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol 2004; 13: 139.
35. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006; 12: 1523.
36. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124.
37. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12: 1133.
38. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319.
39. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237.
40. Cho BK, Rao VP, Ge Q, et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000; 192: 549.
41. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192: 557.
42. Racapé M, Vanhove B, Soulillou JP, et al. Interleukin 7 receptor alpha as a potential therapeutic target in transplantation. Arch Immunol Ther Exp 2009; 57: 253.
43. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naBve and memory CD8 T cells in vivo. Nat Immunol 2000; 1: 426.
44. Carrio R, Rolle CE, Malek TR. Non-redundant role for IL-7R signaling for CD8+ memory T cells. Eur J Immunol 2007; 37: 3078.
45. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008; 118: 1806.
46. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010; 235: 234.
47. Page AJ, Ford ML, Kirk AD. Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009; 14: 643.
48. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T cells with a memory-like phenotype are the dominant cell type following antibodymediated T-cell depletion. Am J Transplant 2005; 5: 465.
49. Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1.
50. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737.
51. Sawitzki B, Bushell A, Steger U, et al. Identification of gene markers for prediction of allograft rejection or permanent acceptance. Am J Transplant 2007; 5: 1091.
52. Burrows SR, Khanna R, Burrows JM, et al. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versushost disease. J Exp Med 1994; 179: 1155.
53. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004; 4: 846.
54. JabsWJ, Maurmann S,Wagner HJ, et al. Time course and frequency of Epstein-Barr virus reactivation after kidney transplantation: linkage to renal allograft rejection. J Infect Dis 2004; 190: 1600.
55. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
56. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularized organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med 1991; 174: 493.
57. Benichou G, Valujskikh A, Heeger PS. Contribution of direct and indirect T cell alloreactivity during allograft rejection inmice. J Immunol 1999; 162: 352.
58. Hsieh HG, Loong CC, Lui WY, et al. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. Transpl Int 2001; 14: 287.
59. Tang JL, Subbotin VM, Antonysamy MA, et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72: 348.
60. Van KC, Boonstra JG, Paape ME, et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9: 1526.
61. Vokaer B, Van Rompaey N, Lemâtre PH, et al. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 2010; 185: 3417.
62. Fàbrega E, Lopez-Hoyos M, San Segundo D, et al. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009; 15: 629.
63. Tajima M, Wakita D, Satoh T, et al. IL-17/IFN-F double producing CD8+ T (Tc17/IFN-F) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12. Int Immunol 2011; 23: 751.
64. Zou Q, Yao X, Feng J, et al. Praziquantel facilitates IFN-F-producing CD8+ T cells (Tc1) and IL-17-producing CD8+ T cells (Tc17) responses to DNA vaccination in mice. PLoS One 2011; 6: e25525.
65. Billerbeck E, Kang YH, Walker L, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci USA 2010; 107: 3006.
66. Sebille F, Gagne K, Guillet M, et al. Direct recognition of foreign MHC determinants by naBve T cells mobilizes specific Vbeta families without skewing of the complementary-determining region 3 length distribution. J Immunol 2001; 167: 3083.
67. Zhou L, Toungouz M, Donckier V, et al. A rapid test to monitor alloreactive responses in whole blood using real-time polymerase chain reaction. Transplantation 2005; 80: 410.
68. Lemmers A, Moreno C, Gustot T, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646.